{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:47:36Z","timestamp":1793710056962,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.urolonc.2022.02.009","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T17:04:51Z","timestamp":1649955891000},"page":"344.e1-344.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6224-9598","authenticated-orcid":false,"given":"Siamak","family":"Daneshmand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris S.G.","family":"Brummelhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal S.","family":"Pohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Aron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Cutie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk A.","family":"Keegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Maffeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Raybold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2022.02.009_bib0001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0002","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0003","doi-asserted-by":"crossref","first-page":"e488","DOI":"10.1016\/j.clgc.2019.01.009","article-title":"Contemporary survival rates for muscle-invasive bladder cancer treated with definitive or non-definitive therapy","volume":"17","author":"Gild","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0004","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0005","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.juro.2010.05.037","article-title":"Lessons learned from 1,000 neobladders: the 90-day complication rate","volume":"184","author":"Hautmann Richard","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0006","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bju.12566","article-title":"Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Data Base","volume":"114","author":"Nielsen","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0007","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.eururo.2013.12.018","article-title":"Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort","volume":"66","author":"Aziz","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0008","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0009","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12894-020-00733-z","article-title":"Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients","volume":"20","author":"Hamid","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0011","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4111\/icu.2020.61.4.390","article-title":"Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer","volume":"61","author":"Carvalho","year":"2020","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0012","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2012.11.015","article-title":"Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the national cancer data base","volume":"63","author":"Gray","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0013","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/JU.0000000000000350","article-title":"A nationwide, population based analysis of patients with organ confined, muscle invasive bladder cancer not receiving curative intent therapy in Sweden from 1997 to 2014","volume":"202","author":"Westergren","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0014","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.euf.2020.01.013","article-title":"Treatment allocation and survival in patients diagnosed with nonmetastatic muscle-invasive bladder cancer: an analysis of a national patient cohort in England","volume":"7","author":"John","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clgc.2013.11.022","article-title":"Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate\/vinblastine\/doxorubicin\/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer","volume":"12","author":"Necchi","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0016","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1002\/cncr.29387","article-title":"Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer","volume":"121","author":"Galsky","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0017","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.juro.2012.10.120","article-title":"Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer","volume":"189","author":"Yuh","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0018","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12894-020-00610-9","article-title":"Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial","volume":"20","author":"Li","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0019","article-title":"Four versus 3 cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: implications for pathological response and survival","volume":"207","author":"Patel Hiten","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3233\/BLC-160072","article-title":"Patterns of bladder preservation therapy utilization for muscle-invasive bladder cancer","volume":"2","author":"Rose","year":"2016","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0021","first-page":"404","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0022","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.eururo.2006.08.038","article-title":"Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta\u2013T1, G1\u2013G2, low- or intermediate-risk, transitional cell carcinoma of the bladder","volume":"51","author":"Maffezzini","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0023","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.urology.2005.03.084","article-title":"Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder","volume":"66","author":"G\u00e5rdmark","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0024","doi-asserted-by":"crossref","first-page":"v142","DOI":"10.1093\/annonc\/mdj970","article-title":"Pharmacokinetic evaluation of gemcitabine and 2\u2032,2\u2032-difluorodeoxycytidine-5\u2032-triphosphate after prolonged infusion in patients affected by different solid tumors","volume":"17","author":"Cattel","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0025","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non\u2013muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0026","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1464-410X.2011.10880.x","article-title":"Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review","volume":"109","author":"Shelley","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0027","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4111\/icu.2019.60.1.35","article-title":"Evaluation of pain and catheter-related bladder discomfort relative to balloon volumes of indwelling urinary catheters: a prospective study","volume":"60","author":"Zugail","year":"2019","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0028","doi-asserted-by":"crossref","first-page":"34.e17","DOI":"10.1016\/j.urolonc.2016.08.005","article-title":"Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: is therapeutic effect owing to chemotherapy or TURBT?","volume":"35","author":"Brant","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0029","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrclinonc.2016.188","article-title":"Systemic, perioperative management of muscle-invasive bladder cancer and future horizons","volume":"14","author":"Funt","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2022.02.009_bib0030","unstructured":"European Association of Urology. Management of patients with high-risk MIBC remains an unmet need. Available at: https:\/\/eaucongress.uroweb.org\/management-of-patients-with-high-risk-mibc-remains-an-unmet-need\/. Accessed 5 October 2021."},{"key":"10.1016\/j.urolonc.2022.02.009_bib0031","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.juro.2011.06.053","article-title":"Induction of caspase mediated apoptosis and down-regulation of nuclear factor-\u03bab and akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells","volume":"186","author":"Jeon Hwang","year":"2011","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392200059X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392200059X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:24:19Z","timestamp":1761042259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392200059X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S107814392200059X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.02.009","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}